Fintel on MSN
BTIG Reiterates Insulet (PODD) Buy Recommendation
Fintel reports that on November 13, 2025, BTIG reiterated coverage of Insulet (NasdaqGS:PODD) with a Buy recommendation.
Fintel reports that on November 7, 2025, Canaccord Genuity maintained coverage of Insulet (NasdaqGS:PODD) with a Buy ...
Insulet (PODD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
5d
Insulet (PODD): Evaluating Valuation After Q3 2025 Results, Upgraded Guidance, and Omnipod Expansion
Insulet (PODD) delivered third-quarter 2025 results that surpassed analyst predictions for both revenue and earnings. This outcome was due to meaningful expansion in its Omnipod insulin delivery ...
SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the “Company”), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the ...
Wall Street expects a year-over-year increase in earnings on higher revenues when Insulet (PODD) reports results for the quarter ended September 2025. While this widely-known consensus outlook is ...
(MENAFN- Investor Brand Network) NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing broad-spectrum antiviral drugs designed to prevent viral escape, will present at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback